- Home
- USPH vs TSHA Comparison
USPH vs TSHA Comparison
Compare USPH & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USPH | TSHA |
|---|---|---|
| Founded | 1990 | 2019 |
| Country | United States | United States |
| Employees | 5500 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | USPH | TSHA |
|---|---|---|
| Price | $74.82 | $4.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $104.50 | $11.11 |
| AVG Volume (30 Days) | 134.1K | ★ 2.8M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | ★ 1.42 | N/A |
| Revenue | ★ $780,990,000.00 | $9,773,000.00 |
| Revenue This Year | $10.49 | N/A |
| Revenue Next Year | $6.46 | $1,228.40 |
| P/E Ratio | $52.13 | ★ N/A |
| Revenue Growth | 16.33 | ★ 17.28 |
| 52 Week Low | $64.75 | $1.13 |
| 52 Week High | $93.50 | $6.02 |
Technical Indicators
Market Signals| Indicator | USPH | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 36.71 | 52.41 |
| Support Level | $72.09 | $4.33 |
| Resistance Level | $76.84 | $4.72 |
| Average True Range (ATR) | 2.41 | 0.28 |
| MACD | 0.15 | 0.03 |
| Stochastic Oscillator | 42.59 | 77.30 |
Price Performance
Historical ComparisonAbout USPH U.S. Physical Therapy Inc.
US Physical Therapy Inc through its subsidiaries operate outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.